目的探讨Look-Locker技术在定量动态增强(DCE)MRI鉴别诊断乳腺良恶性病变的价值。方法搜集本院患有乳腺疾病的女性患者63例,其中恶性组48例,均为浸润性导管癌;良性组15例。另选择48例双侧正常乳腺为对照组。行3.0 T DCE-MR检查,以Look-L...目的探讨Look-Locker技术在定量动态增强(DCE)MRI鉴别诊断乳腺良恶性病变的价值。方法搜集本院患有乳腺疾病的女性患者63例,其中恶性组48例,均为浸润性导管癌;良性组15例。另选择48例双侧正常乳腺为对照组。行3.0 T DCE-MR检查,以Look-Locker序列为基础测量T1定量参数容量转移常数(K^(trans))、速率常数(Kep)和血管外细胞外间隙容积比(Ve),对恶性病变、良性病变及正常腺体组间定量参数行单因素方差分析及LSD法两两比较;最后绘制受试者工作特征曲线(ROC)。结果恶性病变组K^(trans)、Kep、Ve均值为(0.886±0.507)min^(-1)、(1.343±0.483) min^(-1)、0.712±0.241;良性病变组均值为(0.297±0.241) min^(-1)、(0.423±0.283) min^(-1)、0.548±0.216;正常腺体组间均值为(0.019±0.024) min^(-1)、(0.195±0.217) min^(-1)、0.116±0.121。单因素方差分析显示正常腺体组织、良性、恶性病变间K^(trans)(F=76.674,P<0.001)、Kep(F=125.199,P<0.001)、Ve(F=115.930,P<0.001)差异均有统计学意义。三者AUC分别为0.874、0.963、0.686,三者判断乳腺良恶性病变的K^(trans)、Kep、Ve敏感度分别为95.8%、91.7%、41.7%;特异度分别为66.7%、93.3%、93.3%。结论以Look-Locker序列为基础测量的3.0 T DCE-MRI参数K^(trans)、Kep、Ve可以反映乳腺良恶性病变中血管生成的差异,在乳腺病变诊断与鉴别诊断中具有一定价值。展开更多
AIM To assess the accuracy of Look-Locker on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid(GdEOB-DTPA)-enhanced magnetic resonance imaging(MRI) for staging liver fibrosis in chronic hepatitis B/C(CHB/C)....AIM To assess the accuracy of Look-Locker on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid(GdEOB-DTPA)-enhanced magnetic resonance imaging(MRI) for staging liver fibrosis in chronic hepatitis B/C(CHB/C).METHODS We prospectively included 109 patients with CHB or CHC who underwent a 3.0-Tesla MRI examination, including T1-weighted and Look-Locker sequences for T1 mapping. Hepatocyte fractions(He F) and relaxation time reduction rate(RE) were measured for staging liver fibrosis. A receiver operating characteristic analysis using the area under the receiver operating characteristic curve(AUC) was used to compare thediagnostic performance in predicting liver fibrosis between He F and RE.RESULTS A total of 73 patients had both pathological results and MRI information. The number of patients in each fibrosis stage was evaluated semiquantitatively according to the METAVIR scoring system: F0, n = 23(31.5%); F1, n = 19(26.0%); F2, n = 13(17.8%); F3, n = 6(8.2%), and F4, n = 12(16.4%). He F by EOB enhancement imaging was significantly correlated with fibrosis stage(r =-0.808, P < 0.05). AUC values for diagnosis of any(≥ F1), significant(≥ F2) or advanced(≥ F3) fibrosis, and cirrhosis(F4) using He F were 0.837(0.733-0.913), 0.890(0.795-0.951), 0.957(0.881-0.990), and 0.957(0.882-0.991), respectively. He F measurement was more accurate than use of RE in establishing liver fibrosis staging, suggesting that calculation of He F is a superior noninvasive liver fibrosis staging method.CONCLUSION A T1 mapping-based He F method is an efficient diagnostic tool for the staging of liver fibrosis.展开更多
文摘目的探讨Look-Locker技术在定量动态增强(DCE)MRI鉴别诊断乳腺良恶性病变的价值。方法搜集本院患有乳腺疾病的女性患者63例,其中恶性组48例,均为浸润性导管癌;良性组15例。另选择48例双侧正常乳腺为对照组。行3.0 T DCE-MR检查,以Look-Locker序列为基础测量T1定量参数容量转移常数(K^(trans))、速率常数(Kep)和血管外细胞外间隙容积比(Ve),对恶性病变、良性病变及正常腺体组间定量参数行单因素方差分析及LSD法两两比较;最后绘制受试者工作特征曲线(ROC)。结果恶性病变组K^(trans)、Kep、Ve均值为(0.886±0.507)min^(-1)、(1.343±0.483) min^(-1)、0.712±0.241;良性病变组均值为(0.297±0.241) min^(-1)、(0.423±0.283) min^(-1)、0.548±0.216;正常腺体组间均值为(0.019±0.024) min^(-1)、(0.195±0.217) min^(-1)、0.116±0.121。单因素方差分析显示正常腺体组织、良性、恶性病变间K^(trans)(F=76.674,P<0.001)、Kep(F=125.199,P<0.001)、Ve(F=115.930,P<0.001)差异均有统计学意义。三者AUC分别为0.874、0.963、0.686,三者判断乳腺良恶性病变的K^(trans)、Kep、Ve敏感度分别为95.8%、91.7%、41.7%;特异度分别为66.7%、93.3%、93.3%。结论以Look-Locker序列为基础测量的3.0 T DCE-MRI参数K^(trans)、Kep、Ve可以反映乳腺良恶性病变中血管生成的差异,在乳腺病变诊断与鉴别诊断中具有一定价值。
基金Supported by National Natural Science Foundation of China,No.81771893,No.81771802,No.81471718 and No.81401376Outstanding youth Foundation of China Medical University,No.yq20160005
文摘AIM To assess the accuracy of Look-Locker on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid(GdEOB-DTPA)-enhanced magnetic resonance imaging(MRI) for staging liver fibrosis in chronic hepatitis B/C(CHB/C).METHODS We prospectively included 109 patients with CHB or CHC who underwent a 3.0-Tesla MRI examination, including T1-weighted and Look-Locker sequences for T1 mapping. Hepatocyte fractions(He F) and relaxation time reduction rate(RE) were measured for staging liver fibrosis. A receiver operating characteristic analysis using the area under the receiver operating characteristic curve(AUC) was used to compare thediagnostic performance in predicting liver fibrosis between He F and RE.RESULTS A total of 73 patients had both pathological results and MRI information. The number of patients in each fibrosis stage was evaluated semiquantitatively according to the METAVIR scoring system: F0, n = 23(31.5%); F1, n = 19(26.0%); F2, n = 13(17.8%); F3, n = 6(8.2%), and F4, n = 12(16.4%). He F by EOB enhancement imaging was significantly correlated with fibrosis stage(r =-0.808, P < 0.05). AUC values for diagnosis of any(≥ F1), significant(≥ F2) or advanced(≥ F3) fibrosis, and cirrhosis(F4) using He F were 0.837(0.733-0.913), 0.890(0.795-0.951), 0.957(0.881-0.990), and 0.957(0.882-0.991), respectively. He F measurement was more accurate than use of RE in establishing liver fibrosis staging, suggesting that calculation of He F is a superior noninvasive liver fibrosis staging method.CONCLUSION A T1 mapping-based He F method is an efficient diagnostic tool for the staging of liver fibrosis.
